This process ultimately enhances HRR in tumor cells, promoting tumor progression and resistance to DNA damage‐inducing therapy, positioning BCKDK as a potential therapeutic target in clinical breast cancer treatment (Figure S7, Supporting Information). Here, BCKDK is linked to breast carcinoma.